Funded Biotechnology Startups in Oslo
The 14 most recent biotechnology funding rounds logged in Oslo span January 2021 through July 2025, with eight of those closes occurring in 2024 or 2025.
The 14 most recent biotechnology funding rounds logged in Oslo span January 2021 through July 2025, with eight of those closes occurring in 2024 or 2025. The two largest disclosed raises are both Series A rounds: Calluna Pharma at $82M in January 2024 and Actithera at $76M in July 2025 — an uncommon label in a dataset where nine of 14 entries carry a "Series Unknown" classification. OptiNose added $55M in May 2024, bringing the count of rounds at or above $55M to three.
Oncology and immunotherapy are recurring themes: Zelluna Immunotherapy, NEC OncoImmunity AS, Oncoinvent, and Targovax all appear in the data, with round sizes ranging from $4M to $12M. Round sizes vary widely overall, from Circio's $240K close in May 2025 to Calluna Pharma's $82M. Hemispherian is the only company with multiple entries — a $100K Pre-Seed in January 2021 and a $2M Series Unknown round in December 2023.
Most recent rounds
14 shownRelated listings
Frequently asked
What are the largest disclosed rounds among Oslo biotech startups in this dataset?
Calluna Pharma raised $82M in a Series A closed January 2024, Actithera followed with $76M in a Series A in July 2025, and OptiNose raised $55M in May 2024. Those three are the only rounds above $12M among the 14 entries shown; Oncoinvent's $12M Series Unknown round from December 2024 is the next largest.
How does funding activity in 2024–2025 compare to earlier years in this dataset?
Eight of the 14 rounds closed in 2024 or 2025, including the three largest disclosed raises. The 2021–2023 window accounts for the remaining six entries, which skew toward smaller amounts — the largest among them is Calluna Pharma's $82M in January 2024, which straddles the boundary.
What funding stages appear most often, and which are rare?
The majority of rounds carry a 'Series Unknown' classification — nine of the 14 entries. Series A appears twice (Actithera and Calluna Pharma), Seed twice (NoMy and NEC OncoImmunity AS), and Pre-Seed and Post-IPO Equity once each (both Hemispherian and Nordic Nanovector, respectively).
Which companies in this dataset focus on oncology or immunotherapy?
At least four companies operate in those areas: Zelluna Immunotherapy, NEC OncoImmunity AS, Oncoinvent, and Targovax. Their disclosed rounds range from $4M (Targovax, March 2023) to $12M (Oncoinvent, December 2024).
Has any Oslo biotech company in this dataset raised multiple rounds?
Hemispherian appears twice — a $100K Pre-Seed in January 2021 and a $2M Series Unknown round in December 2023 — making it the only company with more than one entry across the 14 rows shown.
What is the most recent funding event, and which companies closed rounds in 2025?
Actithera's $76M Series A on July 9, 2025 is the most recent entry. Three other companies closed rounds in 2025: Circio ($240K Series Unknown, May 13), NoMy ($1M Seed, May 7), and Zelluna Immunotherapy ($5M Series Unknown, March 3).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.